Dario Cattaneo

Vision Statement

I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!

 

  • 2008-present, Head, Laboratory of Pharmacokinetics and Therapeutic Drug Monitoring, Unit of Clinical Pharmacology, L. Sacco University Hospital, Milano, Italy
  • 2016-present, Coordinator of the outpatient clinics for the management of polytherapies in HIV-infected patients, L. Sacco University Hospital, Milano, Italy
  • 2004-2013, Component (Pharmacologist) of the Ethical Committee of the Scientific Institute E. Medea, Bosisio Parini, Lecco, Italy
  • 2003-2008, Component (Pharmacologist) of the Ethical Committee of the Bolognini Hospital of Seriate, Bergamo, Italy
  • 2004-2008, Head, Unit of Pharmacology and Pharmacogenetics, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
  • 1997-2003, Research fellow, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

 

  • 2010-present, Assistant professor in Pharmacology, Faculty of Medicine, University of Milano, Italy
  • 2003-2011, Assistant Professor, Master in Transplant Medicine, University of Milano Bicocca, Italy
  • 2005-2008, Educational coordinator, Maastricht University (Belgium), within the Research Elective Agreement with the Mario Negri Institute for Pharmacological Research, Bergamo, Italy
  • 2004-2008, Assistant Professor, Master in Clinical Research, University of Milano, Italy
  • 2013-2017, Assistant Professor, Master in Pharmacovigilance and Pharmacoepidemiology, University of Naples, Italy
  • 1984-1989, High school diploma in Chemistry (Bergamo, Italy)
  • 1990-1995, Pharmacy Degree (University of Milano, Italy)
  • 1997-2000, Post-graduation specialization in Pharmacological Research (Mario Negri Institute for Pharmacological Research, Bergamo, Italy)
  • 1998-2001, Post-degree Specialization in Pharmacology (University of Milano, Italy)
  • 2001-2005, PhD in Biomedical Sciences (Open University, London, UK)
  • 2005-present, International Association of Therapeutic Drug Monitoring and Clinical Toxicology
  • 2006-present, Italian Society of Pharmacology
  • 2016-present, Italian Society of Infectious Diseases and Tropical Medicine
  • 2019-present, European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
  • 2009-2016, American College of Clinical Pharmacology
  • 2018-present, Italian Federation of Human and Animal Mycology
  • 2001, Winner of the E. Cofferati award for the research activity in the field of immunosuppressant pharmacology
  • 2010, Winner of the D.E.I. Onlus Foundation award for the best emerging profiles in the field of clinical pharmacology
  • Author of nearly 250 publications on peer reviewed indexed international journals, cited more than 6500 times, H-index: 38
  • 7 book chapters
  • Invited speaker for nearly 50 international congresses
  • Invited speaker for nearly 200 national congresses
  • Referee activities for dozens of indexed international journals (> 500 manuscripts reviewed)
  • Member of the editorial board of European Journal of Drug Metabolism and Pharmacokinetics
  • Member of the editorial board of Therapeutic Drug Monitoring
  • Vice chair of the anti-infective committee within the IATDMCT society
  • Member of the ESCMID PK/PD of Anti-Infectives Study Group
  • Member of the board of directors of the Italian Federation of Human and Animal Mycology
  • Therapeutic drug monitoring (mainly anti-infective agents, immunosuppressants, and central nervous system drugs)
  • Pharmacokinetic studies both in healthy volunteers and in patients
  • Application of pharmacogenetics as diagnostic tool for the optimization of drug therapies
  • Antimicrobial stewardship
  • Study and assessment of potential drug-drug interactions in real life settings
  • Evaluation of potential inappropriate drug prescribing in fragile patients (deprescribing)
  • Development and validation of analytical methods for the quantification of drugs in different biological matrices
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.